REGULATORY FRAMEWORK FOR AI-DEVELOPED DRUGS AND IMPLICATIONS ON CLINICAL TRIALS, AND ADEQUACY OF DATA PROTECTION SAFEGUARDS FOR NATIONAL PATIENT DATA

NOTICE PAPER NO. 803

NOTICE OF QUESTION FOR WRITTEN ANSWER

FOR THE SITTING OF PARLIAMENT ON OR AFTER 06 MAY 2026

Name and Constituency of Member of Parliament

Mr Yip Hon Weng

MP for Yio Chu Kang

Question No. 1427

To ask the Coordinating Minister for Social Policies and Minister for Health (a) whether the Ministry has studied if AI-developed drugs can shorten or bypass clinical trials; (b) if so, how will the regulatory approval of AI-developed drugs differ from conventional products; (c) what regulations currently govern AI healthcare innovations; and (d) whether existing personal data protection and cybersecurity safeguards can prevent data leakage when AI accesses national patient data for product conceptualisation.

Answer

1        Both AI-developed and conventionally developed drugs must meet the same international standards of quality, safety, and efficacy. The Health Sciences Authority’s regulatory approach is aligned with international agencies, such as the U.S. Food and Drug Administration and the European Medicines Agency, that have outlined key principles on the responsible use of AI in drug development.

2        Patient data is robustly protected, including when used for AI development. Existing data protection and cybersecurity safeguards, including those under the Personal Data Protection Act, ensure that patient confidentiality is maintained and that the data is protected.

3        We will continue to monitor developments and strengthen our safeguards as needed.